Navigation Links
HIV Virus Emerging Drug Resistant In UK, Prompting Fear Of A Second Epidemic

Reports of highest resistance rates of the HIV virus in the UK has come just in time before the World AIDS Day that is to be celebrated on December 1st. This has created panic // among the scientific community, raising a possibility of a second wave epidemic of resistant virus.

Anti-retroviral drugs are currently used in the management of AIDS victims. The currently available drugs are Zidovudine, Stavudine, Lamivudine, Abacavir, Indinavir, Efavirenz, Nevirapine and Didanosine. A combination of these drugs is usually used for anti-retroviral therapy against the virus.

The researchers set to determine the sensitivity of the HIV positive patients, before embarking on the treatment. More than 2000 patients listed in the national health records between 1996 and 2003 were tested.

Analysis of the results obtained revealed that 335 people showed some degree of resistance to one or more antiretroviral drugs in total. Most of these people – 257 – were resistant to drugs within one class only, 44 cases showed resistance to drugs within two classes and 34 showed resistance to drugs within all three commonly used drug classes.

The figures account for a resistance rate of approximately 14% rate of resistance to one or more of the drugs used. It had mounted up to an alarmingly 19% during the time period of 2002-2003. This is much higher in comparison to rates in USA, France and Europe where it is 7, 6 and 10 % respectively.

The authors say: ‘The United Kingdom has among the highest reported rates of primary resistance to HIV drugs worldwide. By limiting the therapeutic options for a significant number of patients, the secondary epidemic of drug resistant HIV represents a major clinical and public health problem.’

The findings of the present study could mask the large reductions in deaths and improvements to health in people with HIV.
br>
'"/>




Page: 1

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Ebola Virus - Outbreak Claims More Lives In Uganda.
3. Experimental treatment for Ebola Virus Shows promising results in mice
4. Virus Combats Brain Tumour
5. Virus killer
6. Pain Killers Keep the Virus Away
7. Measles Suppresses AIDS Virus
8. Virus connection to cervical injury
9. Virus Helps Remove Brain Cancer
10. Origin Of SARS Virus Discovered
11. New Molecule that can stop the growth of Viruses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... 19, 2017 , ... Aerolib Healthcare Solutions ... Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, Utilization Review ... of Disease Specific Documentation Improvement. , The Aerolib Learning Management System is ...
(Date:1/19/2017)... ... 19, 2017 , ... With the cold weather here, many people will have to clear snow ... clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... Commission for the proper use of snow blowers:, , When removing ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is ... year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday ... clinic’s leading recovery program. , “We know it’s easy to get carried ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... recently provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health ... facility were used to facilitate a recapitalization of MedPro led by Harren Equity ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: